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The Ala-30 and Asn-32 residues involved in the major anlipurallcl /Lsheet struclurc of human CpidCrlIIdl growth frr’daor (hEGF) were substituted 
with various umino acid residues, nnd the receptor-binding uffinitics of the nine variant IrEGFs were dctcrmincd by the USC of human KB cells. 
The Ala-3O+Arg. Ala-30-tHis and Ala-30+Phc substitutions drastically reduced the binding allinity, suggesting that the side chain in position 
30 or AIn-30 of hEGF is rcquircd 10 be small for ~hc rcccplor binding, The Asn-32+Asp substitution significantly reduced lhc binding aflinity. 
while me Asn-32-tHis vnrium could bind 10 the rcccplor as well as to the wild-lypc hEGF. Thcrcforc, it seems to bc importam for receptor binding 
thal ihc side chain in poshion 32 does no1 have a ncgalivc harvc but dots have un NH group. Thus. we propose that. in the ligand-receptor complex. 
~hc rcccplor rccognizcs, on one side of the amipnrallcl @hcct slructurc of hEGF, a wider contact area lhan previously suggested. 
Epidcrmul growth fxlor; She-dircctcd mutagen&: Human cpidcrmal growth factor rcceplor; Protein engineering 
1. INTRODUCTtON 
Epidermal growth factor (EGF) promotes cell prolif- 
eration through muhi-step signal transduction triggered 
by binding of EGF to its receptor on the surface of 
target cells [l-3]. However, the mechanism of the recep- 
tor binding of EGF has not been fully elucidated at the 
molecular structure level. So far, several amino acid 
residues have been found to be important for the recep- 
tor binding, for example Arg-41 and Lcu-47 [4-IO]. 
Chemically synthesized peptides containing residues 
20-31 of EGF bind, though weakly, to the receptor, 
suggesting the importance of this region for the receptor 
binding [I 1,121. By nuclear magnetic resonance (NMR) 
spectroscopy, it has been shown that this segment (resi- 
dues20-31) of EGF is involved in the major antiparallel 
@-sheet structure I1 3-l 71. In human EGF (hEGF), resi- 
dues 18-23 and 28-33 form a p-sheet structure and 
Abhrwhrims: EGF, epidcrmal growth factor; hEGF. humun EGF; 
[lzsl]mEGF, r~%tbeled mouse EGF; NMR, nuclear magnetic reso- 
nancc; NOE, nuclear Ovcrhauscr cffecu 2D NOESY, two-dimcn- 
sional nuclear Overhauscr effect spectroscopy. 
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residues 2427 form a /I-turn, where the side chains of 
residues 19, 21, 23-28. 30 and 32 are exposed on the 
protein surface (Fig. 1) [13,143. These exposed residues 
have the potential of interacting directly with the recep- 
tor. Among the residues on the /?-strand involving rcsi- 
dues 19-23, Ile-23 has been shown to be important for 
the receptor binding [ 18.191. Further, a combination of 
mutagenesis and NMR studies have shown that the side 
chain of lie-23 is directly recognized by the receptor 
[191. 
In contrast, the role of the other B-strand, involving 
residues 28-33, in the receptor binding has not been 
elucidated, because no mutagenesis tudy has been 
made of Ala-30 and Asn-32. In the present study. we 
substituted Ala-30 and Asn-32 of hEGF and examined 
their involvement in the receptor binding. 
2. MATERIALS AND METHODS 
2. I. Prqururiorr of ItEGF vudunrs 
Mutations were introduced into the synthclic gene for LEGF on 
plasmid pTAlS23 [20] using a Muta-Gcnc kit (Bio-Rod) [19]. Esrlre- 
rick co/i strain YK537 was used as a host for the pTAl522 dcriva- 
tivcs bearing hEGF variant gcncs. Biosynthesis and purification of 
variant proteins were carried out as described [l9]. 
2,2. Assuy y/h EGF vuriurtrs 
Concentrations of the wild-type and variant hEGFs were deur- 
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mined by amino acid composition analysis wilh an L-8500 system 
(Hitachi, Tokyo, Japan). The receptor binding affinities of hEGF 
variants were determined by radio-receptor compelition assay; inhibi- 
tion of the binding of lWabeled mouse EGF ([‘z’I]-mEGF) (Amer- 
sham, specific activity: 3,7 MBq/pg) to human KB cells (Dainippon 
Pharmaceurical Co., Osaka, Japan) was measured as described [II]. 
2.3. NMR mwsurtmett~s o~IIEGF voriurtrs 
The 500-MHz two-dimensional proton NMR spectra of the wild- 
type hEGF, the Ala-30-tPhe variant and the Asn-3?+Asp variant 
(I .S mM, pH 2.5 and WC) were measured by two-dimensional nu- 
clear Overhauser effect spectroscopy (2D NOESY) [2?] (mixing time 
= 80 or 100 ms) as described [19]. 
3. RESULTS AND DISCUSSION 
By site-directed mutagenesis, Ala-30 was replaced by 
Arp, Gly, His, Phe and Val, and Asn-32 was replaced 
by Asp, His, Phe and Val. These variant hEGFs were 
obtained with nearly the same yield as that of the wild- 
type hEGF. The affinities of the purified wild-type and 
variant hEGFs to human KB cells were determined in 
competition with [‘z51]n~EGF (Fig. 21, The lC5,, values 
of hEGFs were estimated from the concentrations of the 
proteins at which the amount of cell-bound [‘z51]mEGF 
was reduced to 50% of the maximum level. Relative 
binding affinities were obtained from ICsO (wild-type)/ 
ICso (variant) (Fig., 3). 
Substitution of Ala-30 with Val, a slightly larger res- 
idue than Ala, slightly affected the binding affinity (Fig. 
3). By contrast, substitutions with much larger residues, 
Phe and His, drastically reduced the binding affinity of 
hEGF down to 2.8 and 3.3%, respectively. To examine 
effects of the Ala-30+Phe substitution on the tertiary 
structure of hEGF, we measured 2D NOESY spectrum 
of the Ala-30+Phe variant (Fig. 4B). As sensitive 
probes for the tertiary structure of hEGF, we focused 
our attention on the nuclear Overhauser effects (NOES) 
of Tyr-22 and Tyr-29 in a hydrophobic ore [ 13,143, as 
we did previously for the Ile-23+Asp variant of hEGF 
[ 191. The inter-residue NOES due to the formation of the 
secondary and tertiary structures as well as the intra- 
residue NOES were observed for the variant hEGF to 
the same extent as those for the wild-type hEGF (Fig. 
4A). For example, the NOE cross-peak for the pair of 
the ring protons of Tyr-22 and the a-proton of Tyr-29 
(cross-peak a, Fig. 4B), and the NOE cross- peak for the 
cr-protons of Tyr-22 and Tyr-29 (data not shown) were 
observed in both spectra, indicating that the substitu- 
tion did not affect the antiparallel P-sheet structure of 
hEGF. Further, for both proteins, the NOE between the 
ring protons of Tyr-29 and the @‘-protons of 
Tyr-13 were observed (cross-peak b, Fig. 4A and B), 
indicating that the hydrophobic ore structure involving 
Tyr-13, Tyr-22 and Tyr-29 [ 13,141 was hardly affected 
by the M+SO+Plte substitution. From these results we 
concluded that the tertiary structure of the Ala-30+Phe 
variant is practically the same as that of the wild-type 
hEGF. Therefore, the drastic loss of the affinity indi- 
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Fig. I, Schematic view of lhe major antiparallel P-sheet Strtxlure in 
hEGF, 
cates the importance of the side chain of Ala-30 for the 
receptor binding. Further, substitution of Ala-30 with 
another large residue, Arg, remarkably reduced the af- 
finity to 9.6%. These results indicate that the side chain 
of the residue 30 is required to be small. When Ala-30 
was substituted with Gly, a smaller esidue than Ala, the 
affinity was reduced to 31%, possibly because Gly was 
too small. 
In the case of Ile-23, the side chain is strictly recog 
cized by the receptor [19]; the Ile-23+Ala substitution 
reduced the affinity of hEGF down to 17% while the 
Ala-30-aVal substitution reduced the affnity to 57%. 
Thus, the recognition of Ala-30 by the receptor is less 
strict than that of Ile-23. The position corresponding to 
Ala-30 of hEGF is occupied by a relatively small residue 
in other EGFs; Thr in mouse EGF, Val in rat EGF and 
Ala in Guinea-pig EGF [23-251, also indicating the re- 
quirement of a small residue in this position. The impor- 
tance of hydrophobicity of the segment involving resi- 
dues 19-29 has been proposed [26]. In contrast, the 
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Fig. 2. Compcthion receptor binding ~f[~“ll-mEGF vs. the wild-type 
hEGF and variant hEGFs which have a mutation in poshion 30 (A) 
or 32 (B), 
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Fig. 3. Rcll-ltivc binding ;~lIini~ics orv;iriunt hEGFs, The number on 
the right side oTlhc b:~r is the WIUC or the rclxtivc binding ulhity ($6) 
compnrcd to hat ol’ the wild-type hEGF. 
hydrophobicicy of lhc side chain in position 30 is not 
important for the receptor-ligand interactions (mouse 
EGF has a hydrophilic residue, Thr, in the position 
corresponding to Ala-30 1231 . Thus in position 30. a 
relatively small side chain is required for the receptor 
binding, 
The As11 residue in position 32 is strictly conserved 
among all EGFs [23-251. When this residue was substi- 
tuted with Asp, the affinity of hEGF was remarkably 
reduced down to 6.5% (Fig. 3). As in the case of the 
Al+SO+Phc variant, we mcasurcd 2D NOESY spcc- 
trum of the Asn-32+Asp variant (Fig, 4C) and found 
that the spectrum was practically the same as that of the 
wild-type hEGF. Thus we concluded thal the Asn. 
32+Asp substitution had a negligible ffect on the terti- 
ary structure of hEGF. Therefore the remarkable reduc- 
tion in the affinity by the Asn-32+Asp substitution 
indicates the importance of Asn-32 for receptor binding. 
Replacement of Asn-32 with an uncharged residue, Val, 
less significnntly reduced the affinity of hEGF. Proba- 
bly, the reduction in the binding affinity upon the 
Asn+Asp substitution was caused by the introduction 
of a negatively charged side chain in position 32. Re- 
placement of Asn-32 with Phe, a large and uncharged 
residue. reduced the affinity of hEGF more than the 
replacement with Val. The reduction in the affinit} 
upon the Asn+Phe substitution suggests that a large 
side chain in position 32 is unfavorable for receptor 
binding. On the other hand, replacement by another 
large residue, His, did nut reduce the binding affinity. 
Since the affinity measurement was performed at pH 
7.4, it is likely that His was not positively charged and 
therefore had one NH group. This NH group may act 
in place of that of Asn. Thus, in position 32. a residue 
with an NH group in its side chain is favorable for 
receptor binding of hEGF. 
In summary, we have shown here that the side chains 
of Ala-30 and Asn-32 are important for the binding of 
hEGF to the receptor. The residue in position 30 is 
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Fig. 4.2D NOESY spcctra (for pairs of the aromatic ring protons and 
aliphalic protons) of the wild-type hEGF (A). the Ala30+Phs varhnl 
(B) and thu Asn-J&Asp variani (C). The cross-peaks on the solid 
lines wcrc due to the inlcr-residue NOES (indialcd with arrows and 
Ictlcrs. ;i and b) und intru-residue-NOES from the ring protons or 
Tyr-22 or Tyr-29, 
required to be rather small, indicating that a large resi- 
due in this position disturbs the proper interaction be- 
tween EGF and its receptor. A residue with an NH 
group in position 32 is favorable for receptor binding, 
suggesting the existence of a hydrogen bond acceptor in 
the EGF binding region on the receptor. Probably, the 
receptor directly binds with the p-strands of hEGF in- 
volving residues 30 and 32. 
Previously, a peptide segment, residues 20-31, of 
hEGF had been found to bind weakly with the receptor 
[ 1 I]. In fact, Ile-23 in a p-strand, and Ala-25 and Leu-2B 
in a p-turn have been identified to be important for 
receptor binding [18,19,26]. In addition to these three 
residues, in the present study, we have identified two 
important residues, Ala-30 and Asn-32, in the other 
p-strand. Thus, a wide region of the major antiparallel 
p-sheet structure of hEGF, not simply the region of 
residues 23-26, is involved in the receptor binding. It 
should be noted here that the side chains of these five 
important residues are located all on the same side of 
the/?-sheet s ructure (Fig. 1). Thus, we propose that the 
receptor binds with a wide contact area on the exposed 
side of the major antiparallel B-sheet structure ofhEGF. 
including Ile-23 in a p-strand, and Ala-2S and Leu-26 
in a b-turn, and Ala-30 and Asn-32 on the other p- 
strand. 
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